AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

SUSTAINED EFFICACY1 WITH NO EVIDENCE OF “WEARING OFF”2

Episodic Migraine

Patients experienced significantly more migraine-free days with AJOVY vs placebo in the HALO + Long-Term Extension Studies1,3-5

See Study Design >

Line chart describing clinical trial data of the pivotal HALO Episodic Migraine trial from months 1 to 3 and Long-Term Extension study from months 3 to 12.

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

*Mean baseline of 8.9 migraine days per month with monthly dosing.1

†Reduction in monthly average number of migraine days from the Long-Term Extension study was 6.4 with quarterly dosing.5

PRIMARY ENDPOINT

Patients randomized to monthly dosing had a mean baseline of 8.9 migraine days per month and experienced, on average1:

4.3 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).3,4

Patients randomized to quarterly dosing had a mean baseline of 9.2 migraine days per month and experienced, on average1:

4.2 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).3,4

No evidence of “wearing off” with AJOVY was observed from one dose to the next2

POST HOC WEEKS 1-3 VS 4

Mean number of weekly migraine days during weeks 1-3 vs week 4
at months 3, 6, 9, and 15 with monthly dosing2‡

Bar chart showing Episodic Migraine post hoc analysis of mean number of weekly migraine days during weeks 1-3 vs week 4 at months 3, 6, 9, and 15 with monthly dosing.

POST HOC WEEKS 1-2 VS 11-12

Mean number of weekly migraine days in weeks 1-2 vs weeks 11-12
with quarterly dosing2‡

Bar chart showing Episodic Migraine post hoc analysis of mean number of weekly migraine days in weeks 1-2 vs week 11- 12 with quarterly dosing.

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

‡Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (monthly, n=305; quarterly, n=306) and 432 from the HALO EM study (monthly, n=215; quarterly, n=217) had received AJOVY during the respective HALO study and were included in post hoc analyses during the long-term, open-label extension study2

NOW is the time for AJOVY

In clinical trials, AJOVY reduced migraine days by 50% or more for some patients3

SECONDARY ENDPOINT1

≥50% REDUCTION

in monthly number of migraine days with monthly dosing

47.7% vs 27.9% with placebo
(P<0.001)

EXPLORATORY ANALYSIS3

≥75% REDUCTION

in monthly number of migraine days with monthly dosing

27.1% vs 15.4% with placebo
(Exploratory analysis)

EXPLORATORY ANALYSIS3

100% REDUCTION

in monthly number of migraine days with monthly dosing

10.1% vs 4.5% with placebo
(Exploratory analysis)

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Similar reductions seen with quarterly dosing in chronic migraine patients§

§With quarterly dosing for episodic migraine patients, reduction in monthly average migraine days: 44.4% of patients achieved a ≥50% reduction vs 27.9% with placebo (P<0.001), 25.8% achieved a ≥75% reduction vs 15.4% with placebo (exploratory analysis), and 8.5% achieved 100% reduction vs 4.5% for placebo (exploratory analysis).1,3

​

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Blumenfeld AM, Stevanovic DM, Ortega M, et al. Headache. 2020;60(10):2431-2443. 3. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 4. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999-2008. 5. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487–e2499.